# Inhibitors

## **Atuzabrutinib**

Cat. No.: HY-132808 CAS No.: 1581714-49-9 Molecular Formula:  $C_{30}H_{30}FN_{7}O_{2}$ 

Molecular Weight: 539.6 Btk Target:

Pathway: Protein Tyrosine Kinase/RTK

Storage: 4°C, sealed storage, away from moisture and light

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (185.32 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.8532 mL	9.2661 mL	18.5322 mL
	5 mM	0.3706 mL	1.8532 mL	3.7064 mL
	10 mM	0.1853 mL	0.9266 mL	1.8532 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.63 mM); Clear solution

### **BIOLOGICAL ACTIVITY**

Description	Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling $^{[1]}$ .
In Vivo	PRN473 (20 mg/kg) significantly reduces intravascular crawling and neutrophil recruitment into inflamed tissue in a model of sterile liver injury, down to levels seen in Btk-deficient animals <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Herter JM, et al. PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. Br J Pharmacol. 2018;175(3):429-439.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com